- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 4 - From Animal Models to Human Bodies
Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.
Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.
“Each patient, maybe each tumor, has a different profiling and the mechanism … may be different as well,” he said.
While there have been studies showing the potential for biomarkers, there need to be prospectively designed clinical trials to validate the data, he added.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
